LAVA Therapeutics NV at JPMorgan Healthcare Conference Transcript
Good morning, my name is Daniel Wolle. I'm one of the analysts on the SMID Cap team at J.P. Morgan. It's my pleasure to introduce Steve Hurly from LAVA Therapeutics. (Conference Instructions) Without further ado, Steve.
Thank you, Daniel, and thank you to J.P. Morgan for the opportunity to participate in this wonderful conference. My name is Steve Hurly, I'm the President and Chief Executive Officer of LAVA Therapeutics. I appreciate everybody's time today. Before I begin, this is our forward-looking statements. We'll be making forward-looking statements. Please read thoroughly before making any investment decisions.
So we at LAVA Therapeutics are focused on developing next-generation cancer therapeutics. I'm sure you're all quite familiar with the first generation of T-cell engagers, CD3 engagers. Looking at a broad mixed bag of cells, our approach is to utilize the same engager approach over that subpopulation of T-cells Vgamma9 Vdelta2 family inside of the gamma delta T
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
